SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Genmab kündigt erste Phase-3-Daten zu Epcoritamab plus Lenalidomid bei Lymphom an

Valid market news retained in the public archive without immediate LiveCast distribution.

Related stories